Protein (2)
Launched (2)
Human (2)
His Tag (1)His Tag & Avi Tag (1)
Unconjugated (1)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HLG-H52E9 | HEK293 | Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein (MALS verified) | ||||
HLM-H82E4 | HEK293 | Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Monomer, MALS verified) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Osugacestat | AL-101(BMS); BMS-906024 | Phase 2 Clinical | Bristol-Myers Squibb Company, Glaxosmithkline Plc | Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Adenoid Cystic; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



